ONPATTRO® (patisiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This medication reduces the production of TTR protein through RNA interference and is administered as an intravenous infusion once every 3 weeks.
Product Designer
Engineering Manager
Backend Developer
Product Manager
Simplify patient referrals and offer advanced treatment options with our infusion partnership program.
There may be a better way to manage your condition – explore infusion therapy.